TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

XIFAXAN

RIFAXIMIN
Infectious Disease Approved 2004-05-25
3
Indications
--
Phase 3 Trials
2
Priority Reviews
21
Years on Market

Details

Status
Prescription
First Approved
2004-05-25
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: RIFAXIMIN

XIFAXAN Approval History

Loading approval history...

What XIFAXAN Treats

3 indications

XIFAXAN is approved for 3 conditions since its original approval in 2004. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Travelers' Diarrhea
  • Hepatic Encephalopathy
  • Irritable Bowel Syndrome with Diarrhea
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

XIFAXAN FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. XIFAXAN is a rifamycin antibacterial indicated f...

XIFAXAN Patents & Exclusivity

Latest Patent: Oct 2029

Patents (62 active)

US8642573 Expires Oct 2, 2029
US8969398 Expires Oct 2, 2029
US7928115 Expires Jul 24, 2029
US8829017 Expires Jul 24, 2029
US9421195 Expires Jul 24, 2029
US8946252 Expires Jul 24, 2029
US10335397 Expires Jul 24, 2029
US9629828 Expires Jul 24, 2029
US10314828 Expires Jul 24, 2029
US10709694 Expires Jul 24, 2029
+ 52 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.